Anoxia-induced changes in pyridine nucleotide redox state in cortical neurons and astrocytes.
NAD(P)H autofluorescence was used to verify establishment of metabolic anoxia using primary cultures of cortical neurons and astrocytes. Cells on cover slips were placed in a chamber and O(2) was displaced by continuous infusion of argon. Perfusion with medium at PO(2) < 0.4 mm Hg caused an increase in NAD(P)H fluorescence, albeit to levels lower than that obtained with cyanide. Addition of the nitric oxide-generating agent DETA-NO to the hypoxic medium further increased fluorescence to the level with cyanide. Fluorescence under anoxia remained high in the presence of glucose, but declined in neurons and not in astrocytes when glucose was substituted with 2-deoxyglucose. Reoxygenation of neurons resulted in a decline in fluorescence and a loss in fluorescent gradient between fully reduced and fully oxidized (plus respiratory uncoupler). We conclude that (1) DETA-NO is useful for generating metabolic anoxia in the presence of argon (2) Exogenous glucose is necessary to maintain NAD(P)H in a reduced state during metabolic anoxia in neurons but not astrocytes (3) Neurons undergo a partially irreversible decline in NAD(P)H fluorescence during metabolic anoxia and reoxygenation that could contribute to prolonged metabolic failure.
Kahraman
Sibel
S
Anesthesiology, Program in Neuroscience, University of Maryland School of Medicine, 685 W. Baltimore Street, Baltimore, MD 21201, USA.
Fiskum
Gary
G
D000818:Animals; D000963:Antimetabolites / Q000494:pharmacology; D001253:Astrocytes / Q000187:drug effects / Q000378:metabolism*; D002259:Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone / Q000494:pharmacology; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism*; D003847:Deoxyglucose / Q000494:pharmacology; D015194:Diffusion Chambers, Culture; D005260:Female; D005453:Fluorescence; D005947:Glucose / Q000172:deficiency / Q000502:physiology; D000860:Hypoxia / Q000378:metabolism*; D008856:Microscopy, Fluorescence; D009249:NADP / Q000378:metabolism; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D009711:Nucleotides / Q000378:metabolism*; D010084:Oxidation-Reduction; D011190:Potassium Cyanide / Q000494:pharmacology; D011247:Pregnancy; D011725:Pyridines / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D014475:Uncoupling Agents / Q000494:pharmacology
D000963:Antimetabolites; D009711:Nucleotides; D011725:Pyridines; D014475:Uncoupling Agents; D002259:Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone; D009249:NADP; D003847:Deoxyglucose; D005947:Glucose; D011190:Potassium Cyanide